The mission of the ACTG Network is to reduce the burden of disease due to HIV, tuberculosis, and viral hepatitis.
TB programs in NIAID laboratories comprise basic, translational, and clinical research to develop new drugs that dramatically shorten the time necessary to complete effective TB therapy. These programs also aim to increase understanding of the bacterium that causes TB, the progression of the disease, the advantages and shortcomings of current antibiotics, and the underlying reasons for the development of drug resistance.
NIAID has established an extensive tuberculosis (TB) research program that facilitates the translation of basic research findings into new drugs, vaccines and other biologics, diagnostics, and scientific tools for TB. A critical component of NIAID’s support of TB research has been the Tuberculosis Research Units, first established in 1994. The focus of the Units has been to integrate scientific and clinical research disciplines to study aspects of human TB in endemic countries. The TBRU program was expanded in 2014/2015 to the Tuberculosis Research Units Network (TBRU-N), and is comprised of four multi-project awards to study TB latency and persistence and their relation to active TB disease in humans.